Cellectis S.A. (CLLS) Bundle
A Brief History of Cellectis S.A. (CLLS)
Founding and Early Years
Founding and Early Years
Cellectis S.A. was founded in 1999 in France by André Choulika and a group of scientists from the Pierre and Marie Curie University. The company focuses on gene editing technologies, especially utilizing the TALEN (Transcription Activator-Like Effector Nucleases) system for therapeutic applications.
Initial Public Offering
In 2015, Cellectis went public on the NASDAQ under the ticker symbol CLLS. The IPO raised approximately $115 million, allowing the company to expand its research and development efforts.
Key Developments
- In 2017, Cellectis entered into a collaboration with Pfizer, valued at up to $487 million, for the development of CAR-T therapies.
- In 2018, the company reported a revenue of €13.3 million, compared to €4.7 million in 2017.
- In 2020, Cellectis announced its partnership with Allogene Therapeutics to develop allogeneic CAR-T therapies.
Financial Performance
As of the end of 2022, Cellectis posted a total revenue of €26.6 million, significantly increasing from €19.2 million in 2021. The revenue primarily stemmed from collaborations and partnerships.
Recent Developments
In 2023, Cellectis reported a collaboration deal with the University of Pennsylvania that is focused on gene editing. The potential total consideration for this deal could reach $250 million.
Stock Performance
Throughout 2023, Cellectis shares have experienced fluctuations. As of October 2023, the stock price is approximately $3.50, down from a peak of $8.00 earlier in the year.
Market Capitalization
Cellectis S.A. has a market capitalization of approximately $278 million as of October 2023, reflecting the company's valuation based on current stock price and outstanding shares.
Research and Development
Cellectis has invested heavily in research and development, with R&D expenses totaling approximately €52 million in 2022, compared to €45 million in 2021. This reflects a focused commitment to advancing its gene-editing technologies.
Pipeline Overview
| Product | Indication | Status | Partner |
|---|---|---|---|
| UCART123 | Acute Myeloid Leukemia | Clinical Trials Phase 1 | Allogene Therapeutics |
| UCARTCS1 | Multiple Myeloma | Clinical Trials Phase 1 | None |
| UCART19 | B-Cell Malignancies | Regulatory Approval Pending | None |
| UCART20x22 | B-Cell Malignancies | Clinical Trials Phase 1 | None |
Strategic Partnerships
- Pfizer – Collaboration for CAR-T therapies, valued at up to $487 million.
- Allogene Therapeutics – Partnership for allogeneic CAR-T cell therapies.
- University of Pennsylvania – Focused on gene editing technology development.
A Who Owns Cellectis S.A. (CLLS)
Corporate Structure
Corporate Structure
Cellectis S.A. operates as a biotechnology company focused on developing gene-editing technologies. It is incorporated in France and publicly traded on the NASDAQ under the ticker symbol CLLS.
Major Shareholders
The ownership structure of Cellectis S.A. comprises institutional investors, retail investors, and company insiders. As of the latest filings, the major shareholders are:
| Shareholder | Ownership Percentage | Number of Shares Owned |
|---|---|---|
| FMR LLC (Fidelity Investments) | 10.25% | 2,200,000 |
| BlackRock, Inc. | 8.57% | 1,850,000 |
| RA Capital Management, LLC | 5.12% | 1,100,000 |
| Vanguard Group, Inc. | 4.98% | 1,050,000 |
| Company Insiders | 3.65% | 780,000 |
Insider Ownership
Insider ownership provides insight into the confidence that executives and board members have in the company's future. As of the latest proxy statement, the insider ownership breakdown is as follows:
| Name | Position | Ownership Percentage | Number of Shares Owned |
|---|---|---|---|
| André Choulika | CEO | 1.12% | 240,000 |
| Thomas C. H. T. Lubbe | CFO | 0.75% | 160,000 |
| Karine Dussault | COO | 0.23% | 50,000 |
Institutional Ownership Trends
The institutional ownership landscape of Cellectis S.A. reflects a growing interest in biotechnology investments. The following table summarizes recent trends:
| Quarter | Institutional Ownership Percentage | Change from Previous Quarter |
|---|---|---|
| Q1 2023 | 38.2% | +2.5% |
| Q2 2023 | 39.0% | +0.8% |
| Q3 2023 | 40.5% | +1.5% |
Stock Performance
The performance of Cellectis S.A. stock is crucial for understanding market sentiment. As of October 2023:
| Metric | Value |
|---|---|
| Current Stock Price | $6.50 |
| Market Capitalization | $347 million |
| 52-Week High | $15.00 |
| 52-Week Low | $4.30 |
| Year-to-Date Performance | -22% |
Voting Power
The distribution of voting power within Cellectis S.A. is significant for governance and decision-making. The voting rights associated with shares are as follows:
| Category | Voting Power |
|---|---|
| Common Stock | 1 vote per share |
| Preferred Stock | 5 votes per share |
Cellectis S.A. (CLLS) Mission Statement
Company Overview
Company Overview
Cellectis S.A. is a clinical-stage biotechnology company focused on developing innovative therapies based on gene editing technologies. The company aims to create a new class of immunotherapies for the treatment of cancer.
Mission Statement
The mission of Cellectis S.A. is to leverage its proprietary gene-editing technology to develop innovative cell therapies for patients suffering from various forms of cancer. The company is dedicated to advancing the field of immunotherapy through its research and development efforts.
Core Values
-
Innovation: Commitment to pioneering advancements in gene editing.
-
Collaboration: Working with leading academic institutions and industry partners.
-
Integrity: Upholding ethical standards in research and clinical practices.
-
Patient-Centricity: Focusing on developing therapies that significantly improve patient outcomes.
Recent Financial Performance
- Innovation: Commitment to pioneering advancements in gene editing.
- Collaboration: Working with leading academic institutions and industry partners.
- Integrity: Upholding ethical standards in research and clinical practices.
- Patient-Centricity: Focusing on developing therapies that significantly improve patient outcomes.
Recent Financial Performance
| Financial Metric | 2022 Amount | 2023 Q1 Amount |
|---|---|---|
| Revenue | $16.3 million | $4.2 million |
| Net Loss | ($65.2 million) | ($18.5 million) |
| Cash and Cash Equivalents | $108.9 million | $85.3 million |
| R&D Expenses | $49.8 million | $12.6 million |
| Total Assets | $234.1 million | $204.7 million |
Strategic Goals
- Develop advanced CAR T-cell therapies for hematological malignancies.
- Expand preclinical pipeline targeting solid tumors.
- Enhance partnerships with pharmaceutical companies for co-development.
- Achieve key regulatory milestones for investigational products.
Recent Developments
- Develop advanced CAR T-cell therapies for hematological malignancies.
- Expand preclinical pipeline targeting solid tumors.
- Enhance partnerships with pharmaceutical companies for co-development.
- Achieve key regulatory milestones for investigational products.
Recent Developments
As of October 2023, Cellectis has made significant advancements in clinical trials for its lead product candidates. The company reported the initiation of phase 1 trials for its allogeneic CAR T-cell therapies.
Market Position
| Market Metric | Amount |
|---|---|
| Market Capitalization | $360 million |
| Stock Price (as of October 2023) | $6.00 |
| 52-Week Range | $4.50 - $10.50 |
| Employee Count | Approximately 150 |
How Cellectis S.A. (CLLS) Works
Business Model
Cellectis S.A. (CLLS) operates primarily in the field of gene editing and cell therapy. The company focuses on developing innovative therapies for cancer treatment through its proprietary technologies. Its platform centers on U.S. Patent No. 9,491,207, which covers methods for generating genetically modified immune cells. The company collaborates with various pharmaceutical companies to advance its drug candidates.
Key Technologies
- UCART Technology: Universal Chimeric Antigen Receptor T-cell (CAR-T) therapies designed for allogeneic use.
- Gene Editing Platforms: TALEN® technology for precise genome editing in therapeutic applications.
- Clinical Trials: Active trials for therapies aimed at hematological malignancies and solid tumors.
Financial Overview
As of Q3 2023, Cellectis reported a total revenue of $7.3 million. The company's R&D expenses were approximately $10.5 million, while general and administrative expenses were about $3.9 million.
| Financial Metric | Amount (Q3 2023) |
|---|---|
| Total Revenue | $7.3 million |
| R&D Expenses | $10.5 million |
| General & Administrative Expenses | $3.9 million |
| Net Loss | $(6.6 million) |
Recent Collaborations
Cellectis has established partnerships with various biotech firms and academic institutions to enhance its research capabilities and therapeutic developments. Some recent collaborations include:
- Collaboration with Servier Pharmaceuticals to develop UCART therapies.
- Partnership with Pfizer for advancements in cancer therapies.
- Joint research initiatives with MD Anderson Cancer Center.
Market Position
As of late 2023, Cellectis holds a significant position in the gene-editing sector, with a market capitalization of approximately $220 million. The company aims to expand its footprint in the oncology field, focusing on both solid tumors and hematologic malignancies.
| Market Metric | Value |
|---|---|
| Market Capitalization | $220 million |
| Current Share Price | $4.50 |
| 52-Week High | $6.25 |
| 52-Week Low | $3.10 |
Future Prospects
Looking ahead, Cellectis is poised for growth in the gene therapy market which is projected to reach $13 billion by 2025. The company plans to advance multiple clinical programs and increase collaborations, further enhancing its research in CAR-T therapies.
How Cellectis S.A. (CLLS) Makes Money
Business Model Overview
Cellectis S.A. operates primarily in the field of biotechnology, utilizing its proprietary genome-editing technology. The company focuses on developing CAR T-cell therapies for cancer treatment and collaborates with various pharmaceutical companies to create innovative therapeutics.
Revenue Streams
The revenue streams for Cellectis include:
- Research collaborations
- License agreements
- Product sales from clinical trials
Research Collaborations
Cellectis partners with large pharmaceutical companies for joint research initiatives. In 2022, the company reported collaboration revenue of approximately $16 million.
License Agreements
The company earns significant revenue through licensing its technology. As of 2022, Cellectis secured around $35 million in licensing fees from various partnerships.
Product Sales
Cellectis is also engaged in clinical trials for its proprietary treatments. It reported product sales totaling $5 million in 2022, mainly from early-phase clinical trials.
Financial Performance
For the fiscal year ended December 31, 2022, Cellectis reported the following financial results:
| Financial Metric | 2022 Amount (in millions) |
|---|---|
| Total Revenue | $56 |
| Net Loss | ($52) |
| Research and Development Expenses | $45 |
| General and Administrative Expenses | $12 |
Market Presence
Cellectis operates in multiple markets, focusing on CAR T therapies, which is projected to grow to $14.4 billion by 2023 according to various industry reports. This positions the company for potential growth in revenue through expanding its market share.
Investment and Funding
As of 2023, Cellectis has raised over $300 million through various funding rounds since its inception, enabling continued research and commercialization efforts.
Outlook and Future Growth
In 2023, analysts predict growth potential based on ongoing projects and collaborations. Expected revenues from partnered projects could reach $40 million by 2024. The anticipated launch of new products may further bolster revenue streams.
Cellectis S.A. (CLLS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support